THERAPY OF THE RESISTANT FORMS OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA
https://doi.org/10.35754/0234-5730-2019-64-3-353-361
Abstract
Introduction. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) belongs to a rare group of skin lymphoproliferative disorders, which is characterised by panniculitis-like clinical manifestations, the α/β cytotoxic immunophenotype of tumour cells, as well as a multidirectional course from indolent to aggressive forms.
Aim. To examine patients with SPTCL having an aggressive clinical course and characterised by refractoriness to several lines of chemotherapy.
Results. We present two case reports of patients with a generalised lesions and unfavourable prognostic factors, who achieved complete long-term remission of the disease as a result of gemcitabine chemotherapy.
Conclusion. Despite the fact that both observed SPTCL patients demonstrated refractoriness to at least three types of treatment, the use of gemcitabine allowed long-term complete remissions of the disease to be achieved.
About the Authors
L. G. Gorenkova
National Research Center for Hematology
Russian Federation
Russian Federation
Cand. Sci. (Med.), Researcher, Department of Intensive High-Dose Chemotherapy for Hemoblastoses,
125167, Moscow, Novyy Zykovskiy proezd, 4
S. K. Kravchenko
National Research Center for Hematology
Russian Federation
Russian Federation
Cand. Sci. (Med.), Head of the Department of Intensive High-Dose Chemotherapy for Hemoblastoses,
125167, Moscow, Novyy Zykovskiy proezd, 4
M. A. Silaev
National Research Center for Hematology
Russian Federation
Russian Federation
Cand. Sci. (Med.), Surgeon, Scientific and Clinical Department of Hematological Surgery,
125167, Moscow, Novyy Zykovskiy proezd, 4
N. V. Ryzhikova
National Research Center for Hematology
Russian Federation
Russian Federation
Researcher, Laboratory of Molecular Haematology,
125167, Moscow, Novyy Zykovskiy proezd, 4
References
1. Gonzalez C.L., Medeiros L.J., Braziiel R.M., Jaffe E.S. T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991; 15(1): 17–27.
2. Hoque S.R., Child F.J., Whittaker S.J. et al. Subcutаneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003;148 (3): 516–25.
3. Lozzi G.P., Massone C., Citarella L. et al. Rimming of adipocytes by neoplastic lymphocytes:a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006; 28: 9–12.
4. Willemze R., Cerroni L., Kempf W. et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133 (16): 1703– 14. DOI: 10.1182/blood-2018-11-881268
5. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375–2390.
6. Lopez-Lerma I., Penate Y., Gallardo F. Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018; 79(5): 892–8.
7. Rutnin S., Porntharukcharoen S., Boonsakan P. Clinicopathologic, immunophenotypic, and molecular analysis of subcutaneous panniculitis-like T-cell lymphoma: A retrospective study in a tertiary care center. J Cutan Pathol. 2019; 46 (1): 44–51.
8. Willemze R., Jansen P.M., Cerroni L. et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood. 2008; 111(2): 838–45.
9. Michonneau D., Petrella T., Ortonne N. et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017; 97(3): 358–64.
10. Michot C., Costes V., Gerard-Dran D. et al. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol. 2009; 160: 889–90.
11. Bregman S.G., Yeaney G.A.,Greig B.W. et al. Subcutaneous panniculitislike T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol. 2005; 32: 366–70.
12. Margo C.M., Wang X. CCL5 expression in panniculitic T-cell dyscrasias and its potential role in adipocyte tropism. Am J Dermatopathol. 2013; 35: 332–7.
13. Kong Y.Y., Dai B., Kong J.C. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic and molecular study of 22 Asian cases according to WHO-EORTC classification. Am J Surg Pathol. 2008; 32 (10): 1495–502.
14. Ohtsuku M., Miura T., Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a iterature review of published Japanese cases. Eur J Dermatol. 2017; 27(1): 34–41.
15. Yi L., Qun S., Wenjie Z. et al. The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γ/δ T-cell lymphoma may mimic those of rheumatic diseases: a report of 11 cases. Clin Rheumatol. 2013; 32:1169–75.
16. Willemze R. Cutaneous lymphomas with a panniculitic presentation. Seminars in Diagnostic Pathology. 2017; 34(1): 36–43. DOI: 10.1053/j.semdp.2016.11.009.
17. Lee D.W., Yang J.H., Lee S.M. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011; 23(3): 329–37.
18. Sitthinamsuwan P, Pattanaprichakul P., Treetipsatit J. et al. Subcutaneous Panniculitis-Like T-Cell Lymphoma Versus Lupus Erythematosus Panniculitis: Distinction by Means of the Periadipocytic Cell Proliferation Index. Am J Dermatopathol. 2018; 40(8): 567–74.
19. Pincus L.B., LeBoit P.E., McCalmont T.H. et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities. Am J Dermatopayhol. 2009; 31: 520–26.
20. Massone C., Lozzi G.P., Egberts F. et al. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J. Cutan. Pathol. 2006; 33: 418–25.
21. Mizutani S., Kuroda J., Shimura Y. et al. Cyclosporine A for chemotherapyresistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011; 126: 8–12.
22. Jang M.S., Baek J.W., Kang D.Y. et al. Subcutaneous panniculitis-like T-cell lymphoma: successful treatment with systemic steroid alone. J. Dermatol. 2012; 39(1): 96–9.
23. Briki H., Bouaziz J.D., Molinier-Frenkel V. et al. Subcutaneous panniculitis-like T-cell lymphoma: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol. 2010; 163(5): 1136–8.
24. Go R.S., Wester S.M. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systemic analysis of 156 patients reported in literature. Cancer. 2004; 101(6): 1404–13.
25. Mellgren K., Attarbaschi A., Abla O. et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents — an International review of 143 cases. Ann Hematol. 2016; 95(8): 1295–305.
26. Cheson B.D. PET/CT in lymphoma: Current overview and future directions. Semin Nucl Med, 2018; 48(1): 76–81.
27. Ng M., Waters J., Cunningham D. et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005; 92(8): 1352–7.
28. Yim K.L., Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol. 2012; 29(5): 3535–9.
Review
For citations:
Gorenkova L.G., Kravchenko S.K., Silaev M.A., Ryzhikova N.V. THERAPY OF THE RESISTANT FORMS OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA. Russian journal of hematology and transfusiology. 2019;64(3):353-361. (In Russ.) https://doi.org/10.35754/0234-5730-2019-64-3-353-361
Views:
3194
Email this article 
